View Clinical Trial (Medical Research Study)
Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome
| City: |
|
Newark |
| State: |
|
New Jersey |
| Zip Code: |
|
07112 |
| Conditions: |
|
Smoking - Acute Coronary Syndrome |
| Purpose: |
|
Assess the role of a nicotine antagonist in helping patients presenting to hospital with
acute coronary syndrome to stop smoking.
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- active smokers presenting to hospital with an acute coronary syndrome
Exclusion Criteria:
- patients with an acute coronary syndrome who are not active smokers
|
| NCT ID: |
|
NCT01170338 |
| Primary Contact: |
|
N/A |
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Newark, New Jersey 07112
United States
Marc Cohen, MD
Phone: 973-926-7852
Email: marcohen@sbhcs.com
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
June 19, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|